Cag

What is Cag?

A long-acting amylin analog studied for appetite suppression and weight loss, often in combination with GLP-1 agonists.

This profile is educational. It organizes publicly discussed research context for Cag and related naming aliases — it is not a treatment guide.

Proposed mechanism

Activates amylin receptors, slowing gastric emptying and reducing meal size; complementary to GLP-1 pathway effects on satiety.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Moderate human evidence

Preclinical evidence grade: Moderate human evidence

Cagrilintide mimics amylin, a pancreatic co-secreted hormone involved in satiety signaling. Researchers have studied it alone and combined with semaglutide (CagriSema) in phase 2/3 programs. Available evidence suggests additive weight loss versus GLP-1 monotherapy in trial populations. Human evidence remains limited to clinical trial settings; approval status is investigational.

Key uncertainties

• Standalone vs combination benefit
• Regulatory timeline

Research areas being studied

• Obesity
• Combination incretin therapy

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

• Nausea
• Vomiting
• Diarrhea
• Injection-site reactions

Additional risks & considerations

• GI effects
• Combination therapy complexity
• Incomplete long-term data

Regulatory status

Investigational

Investigational; combination with semaglutide under regulatory review in some regions.

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

References & sources

• Enebo LB et al. (2021). Cagrilintide plus semaglutide in obesity — phase 2 results — Lancet. Evidence type: human.